

## CCL4 RABBIT PAB

货号: S216403

产品全名: CCL4 兔多抗

基因符号 ACT2; G-26; HC21; LAG1; LAG-1; MIP1B; SCYA2; SCYA4; MIP1B1; AT744.1; MIP-1-beta

**UNIPROT ID:** P13236 (Gene Accession - BC104226)

**背景:** The protein encoded by this gene is a mitogen-inducible monokine and is one of the major HIV-suppressive factors produced by CD8+ T-cells. The encoded protein is secreted and has chemokinetic and inflammatory functions. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.

**抗原:** Fusion protein of human CCL4

**经过测试的应用:** ELISA, IHC

**推荐稀释比:** IHC: 50-200; ELISA: 1000-5000

**种属反应性:** Rabbit

**克隆性:** Rabbit Polyclonal

**亚型:** Immunogen-specific rabbit IgG


**纯化:** Antigen affinity purification

**种属反应性:** Human, Rat


**成分:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**研究领域:** Immunology


**储存和运输:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 216403(CCL4 Antibody) at a dilution of 1/40(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 216403(Anti-CCL4 Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 216403(Anti-CCL4 Antibody) at a dilution of 1/40.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with fusion protein and then with D220380(Anti-CCL4 Antibody) at dilution 1/40.



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---